The dose escalation indicates favorable safety and supports continued development of RAD202. Traders should monitor upcoming clinical updates, particularly efficacy signals in later-stage trials. This progress may attract investor interest in Radiopharm's radiopharmaceutical platform, especially given the unmet need in HER2+ solid tumors.
Price Chart
Executive Summary
Radiopharm Theranostics announced that its Phase 1 'HEAT' clinical trial for 177Lu-RAD202 has advanced to dose level 3 (130mCi) based on a positive safety review by the Data Safety and Monitoring Committee. This reflects favorable tolerability and continued progression of its oncology radiopharmaceutical candidate in HER2+ advanced solid tumors.
Key Facts
- Phase 1 'HEAT' trial of 177Lu-RAD202 has advanced to Cohort 3 with a dose level of 130mCi
- Decision follows positive recommendation from the independent Data Safety and Monitoring Committee (DSMC)
- Trial is ongoing in Australia in patients with HER2-positive advanced solid tumors
- Previous dose level was 75mCi, announced on October 1, 2025
- Company remains on track to complete Phase 1 dose escalation by end of 2026
Financial Impact
No direct financial impact disclosed; advancement reduces clinical development risk and supports pipeline progress
Risk Factors
- Future clinical results may not show efficacy despite positive safety data
- Next dose levels could reveal new safety concerns
- Development timeline delays possible despite current schedule
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-041266 |
| Document: ea0285541-6k_radiopharm.htm | 0001213900-26-041266 |
| Document: 0001213900-26-041266-index-headers.html | 0001213900-26-041266 |
| Document: 0001213900-26-041266-index.html | 0001213900-26-041266 |
| Document: 0001213900-26-041266.txt | 0001213900-26-041266 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −52.50% | $0.006660 (−66.70%) |
May 6, 2026 24w ago | 3 | $0.0200 $0.0100 | ▼ −50.00% | ▼ −53.83% | $0.006660 (−66.70%) |
Apr 23, 2026 26w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −55.02% | $0.006660 (−66.70%) |
Apr 16, 2026 27w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −57.05% | $0.006660 (−66.70%) |
Apr 8, 2026 28w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −60.46% | $0.006660 (−66.70%) |
Apr 7, 2026 29w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −63.27% | $0.006660 (−66.70%) |
Apr 1, 2026 29w ago | 3 | $0.0200 $0.0100 | ▼ −50.00% | ▼ −64.16% | $0.006660 (−66.70%) |
Mar 27, 2026 30w ago | 6-K | $0.0200 $0.0200 | · 0.00% | ▼ −16.07% | $0.006660 (−66.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers